Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Caladrius Bio (CLBS)

Caladrius Bio (CLBS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer Globe Newswire - Wed Aug 10, 2022

Study to be part of Roche’s Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations ...

CLBS : 0.4264 (-16.44%)
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update Globe Newswire - Thu Aug 4, 2022

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata...

CLBS : 0.4264 (-16.44%)
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates PING, CLBS, MANT PR Newswire - Thu Aug 4, 2022

/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CLBS : 0.4264 (-16.44%)
PING : 28.50 (+0.11%)
MANT : 95.98 (-0.01%)
CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Caladrius Biosciences, Inc. - CLBS Business Wire - Wed Aug 3, 2022

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosciences, Inc. (NasdaqCM: CLBS)...

CLBS : 0.4264 (-16.44%)
Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease Globe Newswire - Tue Aug 2, 2022

Top-line data from all subjects expected by the first quarter of 2023...

CLBS : 0.4264 (-16.44%)

Barchart Exclusives

Is Jack Henry & Associates Stock Underperforming the Nasdaq? Barchart - 1 hour ago
Jack Henry & Associates stock has underperformed the Nasdaq over the past year, but analysts remain moderately bullish about its prospects. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.